Multinationals and domestic drugmakers upping R&D investment in India

17 October 2019

The signs are clear that India is seeing a big rise in pharmaceutical R&D investment, reports The Pharma Letter’s India correspondent.

Multinational drug company Mylan (Nasdaq: MYL) is set to invest $6 billion on capex in India to incentivize R&D activity; biotech major Biocon (BSE: 532523) acquired Chennai-based R&D facility from Pfizer (NYSE: PFE) through its subsidiary Biocon Biologics; Lupin (BSE: 500257) signing a $700 million licensing, development and commercialization agreement with Germany’s Boehringer Ingelheim to develop and commercialize one of its lead MEK inhibitors - all the signs show Indian drug companies moving up the value chain, transforming into complex generic manufacturers with high-end R&D facilities.

With the Indian government said to be considering removing drugs using locally-manufactured active pharmaceutical ingredients (APIs) from price control, leading players are accelerating their drug discovery efforts, seeking to build a robust research pipeline.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK